CSTLMEDIUM SIGNALOPERATIONAL10-K

Castle Biosciences has pivoted its business focus from mental health testing to atopic dermatitis diagnostics while maintaining solid revenue growth and expanding operations.

The company removed all references to mental health conditions and pharmacogenomic testing from its core business description, instead adding atopic dermatitis as a key focus area. This represents a meaningful strategic shift in the company's portfolio and market positioning. The change suggests management is concentrating resources on dermatologic and related diagnostic areas rather than pursuing the mental health market.

Comparing 2026-02-26 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

Castle delivered healthy operational growth with gross profit expanding 18.9% and the company investing meaningfully in expansion through 27% higher capital expenditures. However, total liabilities increased 43% and current liabilities rose 39%, indicating higher operational leverage, while accounts receivable declined 15% despite revenue growth. The financial profile suggests a company scaling operations but with increasing working capital demands and debt obligations to fund growth initiatives.

FINANCIAL STATEMENT CHANGES
Total Liabilities
Balance Sheet
+42.8%
$75.4M→$107.7M

Liabilities grew 42.8% — significant increase in debt or obligations, assess impact on financial flexibility.

Current Liabilities
Balance Sheet
+39%
$49.4M→$68.7M

Current liabilities surged 39% — significant near-term obligations; verify ability to meet short-term debt.

Interest Expense
P&L
-35.3%
$17K→$11K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Capital Expenditure
Cash Flow
+27.2%
$28.3M→$36.0M

Capex increased 27.2% — ongoing investment in capacity or infrastructure for future growth.

Inventory
Balance Sheet
+26%
$8.1M→$10.3M

Inventory built 26% — monitor whether demand supports this build or if write-downs may follow.

Gross Profit
P&L
+18.9%
$44.6M→$53.0M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Accounts Receivable
Balance Sheet
-15.3%
$51.2M→$43.4M

Receivables declined — improved collection efficiency or conservative revenue recognition.

SG&A Expense
P&L
+14.6%
$200.0M→$229.3M

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-27
ADDED
As of February 19, 2026, there were 29,731,198 shares of common stock, $0.001 par value per share, outstanding.
) and foreign countries; the performance of our third-party suppliers; the success of competing diagnostic products that are or become available; our ability to attract and retain key personnel; and our expectations regarding our ability to obtain and maintain intellectual property protection for our products and our ability to operate our business without infringing on the intellectual property rights of others.
Overview Castle Biosciences is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett s esophagus ( BE ), atopic dermatitis ( AD ), uveal melanoma ( UM ).
For our core tissue-based tests, we use multi-analyte assays with algorithmic analysis ( MAAA ) to characterize an individual patient s biology and generate clinically actionable information.
Depending on the specific test, this information may be used to provide information to help guide treatment and patient management decisions including potential responsiveness to therapy and to assist in the diagnosis of a disease.
+7 more — sign up free →
REMOVED
As of February 20, 2025, there were 28,514,109 shares of common stock, $0.001 par value per share, outstanding.
We are an early, commercial-stage company and have a limited operating history, which may make it difficult to evaluate our current business and predict our future performance.
Overview Castle Biosciences is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett s esophagus, uveal melanoma, and in the treatment of mental health conditions.
For our tissue based tests, we use multi-analyte assays with algorithmic analysis ( MAAA ) to characterize an individual patient s biology to inform specific risk of progression.
Test Portfolio and Market Overview Our portfolio consists of test offerings to aid clinicians in the diagnosis and treatment of cancers or precancerous diagnoses in the fields of dermatology, gastroenterology and ophthalmology and a pharmacogenomic ( PGx ) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions.
+7 more — sign up free →
MORE OPERATIONAL SIGNALS
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NOWHIGHServiceNow has fundamentally repositioned itself as an AI-first platform company...
2026-01-29
TSLAHIGHTesla has fundamentally repositioned itself from an electric vehicle company to ...
2026-01-29
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →